Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC [0.03%]
卡介菌膀胱灌注治疗后尿液免疫和微生物组的变化及其与非肌层浸润性膀胱癌疗效的关系
Yuki Oda,Makito Miyake,Nobutaka Nishimura et al.
Yuki Oda et al.
Aim: Intravesical Bacillus Calmette-Guérin (BCG) is the standard therapy for non-muscle invasive bladder cancer (NMIBC); however, many patients experience recurrence or progression. We examined how urinary immune signals...
Disrupting the TGF-β-regulated epithelial-mesenchymal transition, apoptotic and autophagic phenotypes of 3D glioblastoma spheroids via glycolytic inhibition [0.03%]
通过抑制糖酵解干扰三维胶质母细胞瘤球形体的TGF-β调节上皮间充质转化、凋亡和自噬表型
Maellis Payet-Desruisseaux,Alain Zgheib,Bogdan Alexandru Danalache et al.
Maellis Payet-Desruisseaux et al.
Aim: Glioblastoma (GBM), a rare, highly aggressive and chemoresistant brain cancer, exhibits profound metabolic plasticity that relies, in part, on aberrant transforming growth factor-β (TGF-β) signaling. Such plasticit...
Salma Fenniche,Mohamed Oukabli,Yassire Oubaddou et al.
Salma Fenniche et al.
Aim: Chromodomain-helicase-DNA-binding protein 4 (CHD4) is a core NURD remodeling complex ATPase that plays a crucial role as a gene repressor. Its overexpression has been reported in several cancers. In papillary thyroid...
Survival prediction in triple-negative breast cancer: a Cox model with fairness assessment using ISO/IEC TR 24027:2021 in a MENA cohort [0.03%]
基于ISO/IEC TR 24027:2021公平评估的Cox模型在MENA人群中预测三阴性乳腺癌生存率
Mehrshad Alirezaei Farahani,Fateme Sadeghipour,Hamid Reza Marateb et al.
Mehrshad Alirezaei Farahani et al.
Aim: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options and poor survival outcomes. Prognostic models developed in Western cohorts rarely assess algorithmic fairness. This study...
Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer [0.03%]
血凝蛋白作为乳腺癌疾病进展和预后标志物的作用不容小觑
Ogochukwu O Izuegbuna
Ogochukwu O Izuegbuna
Breast cancer is a leading cause of cancer death in women worldwide. One of the major causes of death from breast cancer is metastatic disease, which results from the malignant cells invading and migrating through blood vessels to distant s...
Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis [0.03%]
多西他赛治疗前列腺癌的周疗方案比较：系统评价和频率学网络meta分析
Shree Rath,Fatima Sajjad,Khawaja Abdul Rehman et al.
Shree Rath et al.
Background: Docetaxel is a cornerstone chemotherapy for metastatic hormone-sensitive and castration-resistant prostate cancer. Although the standard triweekly regimen is widely used, weekly and biweekly schedules are ofte...
Benign, persistent, and invasive: mechanistic and translational approaches to middle‑ear cholesteatoma [0.03%]
良性、持久和侵袭性：中耳胆脂瘤的机制和转化方法论研究
Pinelopi Samara,Michail Athanasopoulos,Ioannis Athanasopoulos
Pinelopi Samara
Acquired middle-ear cholesteatoma is a histologically benign keratinizing squamous epithelial lesion that paradoxically exhibits locally destructive, recurrent, and invasive behavior, often resulting in ossicular erosion, hearing loss, laby...
Glioblastoma pathophysiology: roles of aging driven changes in STAT3 interactions with NF-κB dimer components in the modulation of the mitochondrial melatonergic pathway and night-time inflammation resolution [0.03%]
胶质母细胞瘤病理生理学：年龄驱动的STAT3与NF-κB二聚体组分相互作用变化在调节线粒体松果腺激素通路和夜间炎症消退中的作用
George Anderson
George Anderson
Glioblastoma (GBM) is a complex condition with a poorly understood pathophysiology and no effective treatment to date. The present article highlights the role of canonical and non-canonical signal transducer and activator of transcription 3...
Application of explainable artificial intelligence integrating with electronic health record in oncology [0.03%]
可解释的人工智能在肿瘤学中的应用及其与电子健康档案的结合研究
Yuhan Yang,Xici Liu
Yuhan Yang
Machine learning (ML) and deep learning (DL) models applied to electronic health records (EHRs) have substantial potential to improve oncology care across diagnosis, prognosis, treatment selection, and trial recruitment. However, opacity of...
The critical need for robust decision support in the era of precision cancer therapeutics [0.03%]
精准肿瘤治疗时代的稳健决策支持的迫切需求
Maurie Markman
Maurie Markman